C2N Diagnostics (United States)

Recent papers from C2N Diagnostics (United States)

1. Plasma eMTBR-tau243 and p-tau205 as T2 biomarkers for biological staging and prognosis in Alzheimer’s diseaseNature Communications · 2026
2. Plasma Phosphorylated Tau 217 Percentage by Race and Ethnicity in Preclinical Alzheimer DiseaseJAMA Neurology · 2026
3. Plasma eMTBR‐tau243 as a disease biomarker across Alzheimer's disease clinical phenotypesAlzheimer s & Dementia · 2026
4. More efficient screening for preclinical Alzheimer's clinical trials using mixture of expertsAlzheimer s & Dementia · 2026
5. Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's diseaseAlzheimer s & Dementia · 2026
6. Early Alzheimer’s Disease Diagnosis and Blood Biomarkers: Primary Care Physician Attitudes, Perceptions, and Barriers in the USA (P4-12.009)Neurology · 2026
7. Exploring automated plasma phospho-tau217 assays for the diagnosis of Down syndrome-related Alzheimer’s diseaseCommunications Medicine · 2026
8. System changes to empower primary care in Alzheimer's disease detection and care.2026
9. Plasma phosphorylated tau 217 and longitudinal trajectories of Aβ, tau, and cognition in cognitively unimpaired older adultsNature Communications · 2026
10. Implementation of a blood test for Alzheimer's disease in primary care: A pilot studyAlzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 2026
11. The glymphatic system clears amyloid beta and tau from brain to plasma in humansNature Communications · 2026
12. Performance of plasma p-tau217 in distinguishing amyloid and tau pathology differs by cognitive impairment statusJournal of the Neurological Sciences · 2025
13. Modelling the temporal evolution of plasma p-tau217, amyloid PET, tau PET and cognitionBrain · 2026
14. Plasma p‐tau217 predicts PET‐based pathological staging for precision Alzheimer disease assessmentAlzheimer s & Dementia · 2026
15. Plasma Phosphorylated Tau 217 Cutoffs for Amyloid Pathology and Kidney Function, Body Mass Index, and AnemiaJAMA Neurology · 2026
16. Interchangeability of blood‐based biomarkers and PET to identify Alzheimer's disease pathologyAlzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 2026
17. Early Alzheimer's diagnosis: U.S. primary care physicians and use of blood biomarkersAlzheimer s & Dementia · 2026
18. Evidence‐based standardized sample handling protocol for accurate blood‐based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization ConsortiumAlzheimer s & Dementia · 2025
19. Implementation of an Alzheimer’s Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center StudyJournal of Personalized Medicine · 2025
20. Reaching international consensus on the definition of refractory migraine using the Delphi method.2025